TA-65

TA-65 is a branded oral Astragalus-derived supplement discussed for telomeres and healthy aging. Longevity users describe strength, sleep or energy changes, but experiences differ and some effects fade or never appear. A changed telomere test is not proof of a longer life or visible rejuvenation.

An oral supplement, not a peptide. TA-65MD is the branded capsule formulation. Telomeres are protective chromosome ends; telomerase helps maintain them. The commercial skin cream is a separate product, so oral findings do not establish cream benefits. Salvador et al. — randomized TA-65 telomere trial (2016) (Official context · Accessed 2026-09-30) · T.A. Sciences product forms and proprietary strengths (Official context · Accessed 2026-09-30) · FTC final consent order in TA Sciences advertising case (2018) (Official context · Accessed 2026-09-30)

Branded Units are different from generic milligrams. Capsules are sold at 100 or 250 proprietary Units. Forum comparisons with cycloastragenol, astragaloside IV and whole Astragalus extracts involve different products. Users debate identity and absorption; their comparisons do not establish milligram-for-Unit equivalence. T.A. Sciences product forms and proprietary strengths (Official context · Accessed 2026-09-30) · Alternative methods to extend telomeres — page 4 (Community opinion · Accessed 2026-09-30)

Source context — Salvador et al. — randomized TA-65 telomere trial (2016): CMV-positive adults aged 53–87, selected exclusions, biomarker endpoint, company funding and employment/consulting ties. Not life-extension, generic equivalence, felt onset/duration or human PK evidence. PMC copy blocked; publisher body inspected.

Source context — T.A. Sciences product forms and proprietary strengths: Manufacturer promotion, useful only for branded forms and labels; not independent effectiveness, equivalence or safety evidence. Price and purchase instructions intentionally omitted.

Source context — FTC final consent order in TA Sciences advertising case (2018): Historical advertising enforcement, not proof of biological inefficacy, cancer causation or current product prohibition. Initial direct open errored; shorter legacy URL redirected successfully to this exact page.

Source context — Alternative methods to extend telomeres — page 4: Secondhand interview statements and patent inference, not chemical analysis or human equivalence. Dog bioavailability and molecular-structure speculation not adopted as facts; unrelated skin reports belong to other interventions and were excluded.

Strength and vitality are reported benefits. Gramson described being able to exercise with 40-pound barbells while using TA-65, then losing the perceived benefit after roughly six months. Other products, serious stomach bleeding, anemia and iron treatment complicate that account. Gramson's TA-65 follow-up in Epitalon discussion (Personal report · Accessed 2026-09-30)

Sleep changes can be welcome or unsettling. Telo ranked TA-65 above two generic products for vivid dreams after trying it for a couple of months. That was a subjective comparison, not a test of absorption, telomeres or restorative sleep. Telo's cycloastragenol and TA-65 comparisons (Personal report · Accessed 2026-09-30)

Oral TA-65: 6–8 capsules daily in one report. Balance used that daily total for a few months without noticing different dreams. Capsule strength was unstated; it cannot be converted into Units or milligrams. Astragalus, Astragaloside IV — page 70 (Community discussion · Accessed 2026-09-30)

Unsettling dreams and unchanged dreams both occur. Free10 found realistic dreams disturbing enough to change timing; balance noticed no dream change. Dream intensity is not evidence of absorption or brain rejuvenation. Astragalus, Astragaloside IV — page 70 (Community discussion · Accessed 2026-09-30)

Some people want measurable aging markers. A Reddit contributor reported lower CRP after six months alongside NAC and omega-3s, without before-and-after telomere testing. CRP reflects inflammation; this stacked account does not isolate TA-65 or establish telomere lengthening. Best supplements for protecting telomere length? (Personal report · Accessed 2026-09-30)

TA-65 is a branded oral Astragalus-derived supplement discussed for telomeres and healthy aging. Longevity users describe strength, sleep or energy changes, but experiences differ and some effects fade or never appear. A changed telomere test is not proof of a longer life or visible rejuvenation.

Source context — Gramson's TA-65 follow-up in Epitalon discussion: Uncontrolled retrospective report; TA-65 dose unstated. The author's stored-enzyme depletion theory is unsupported and not adopted. Co-use and major health changes prevent attribution.

Source context — Telo's cycloastragenol and TA-65 comparisons: Historical products, anecdotal identity/quality assertions, subjective comparison and no head-to-head measurements. The generic amount is not a TA-65 dose. Later 20 mg wording does not independently restate frequency. No sourcing links or certificate authenticity claims transferred to the article.

Source context — Astragalus, Astragaloside IV — page 70: Unverified products and exposure, retrospective subjective observations. Corrects the frozen ledger's attribution of balance's #2075 report to piet3r. GreenPower used related extracts; no branded-specific adverse-event rate, measured absorption, BBB penetration or causal mechanism follows.

Source context — Best supplements for protecting telomere length?: Product and units unresolved: 250 mg may be confusion with Units, but this cannot be silently corrected. CRP units unstated; no documents, independent verification or causal attribution. Exact numerical CRP claim retained here, not presented as an effect estimate.

Oral TA-65: 6–8 capsules daily in one report. Balance used that daily total for a few months without noticing different dreams. Capsule strength was unstated; it cannot be converted into Units or milligrams. Astragalus, Astragaloside IV — page 70 (Community discussion · Accessed 2026-09-30)

Generic cycloastragenol amounts stay separate. Telo described starting at 10 mg/day and later taking 20 mg after just over three weeks, without restating frequency. That concerned a generic oral product. A Reddit post says “250 mg” daily of TA-65, but its product and units remain unresolved; neither figure supplies branded Unit math. Telo's cycloastragenol and TA-65 comparisons (Personal report · Accessed 2026-09-30) · Best supplements for protecting telomere length? (Personal report · Accessed 2026-09-30)

Drewbo_ comment; retrieved dated search body identifies 23 May 2026, opened body shows a relative edited timestamp. Six-month TA-65, NAC, omega-3 account, literal 250mg, CRP 2.1 to under 0.5 and absent telomere testing. Best supplements for protecting telomere length? (Personal report · Accessed 2026-09-30)

17 August 2012 #2 and 9 April 2015 #6; generic 10 mg/day then 20 mg, just-over-three-week account; later TA-65 couple-month dream ranking. Replies #3–4 discuss mismatched certificate branding. Telo's cycloastragenol and TA-65 comparisons (Personal report · Accessed 2026-09-30)

A year-long telomere trial is separate evidence. In CMV-positive adults aged 53–87, 250 U/day showed a telomere-length signal; 1000 U/day did not show a significant improvement. The paper maps those formulations to 8 and 32 mg active and used 90 days on, 14 days off. These are study amounts and schedules, not community measurements or proof that more is better. Salvador et al. — randomized TA-65 telomere trial (2016) (Official context · Accessed 2026-09-30)

Source context — Astragalus, Astragaloside IV — page 70: Unverified products and exposure, retrospective subjective observations. Corrects the frozen ledger's attribution of balance's #2075 report to piet3r. GreenPower used related extracts; no branded-specific adverse-event rate, measured absorption, BBB penetration or causal mechanism follows.

Source context — Telo's cycloastragenol and TA-65 comparisons: Historical products, anecdotal identity/quality assertions, subjective comparison and no head-to-head measurements. The generic amount is not a TA-65 dose. Later 20 mg wording does not independently restate frequency. No sourcing links or certificate authenticity claims transferred to the article.

Source context — Best supplements for protecting telomere length?: Product and units unresolved: 250 mg may be confusion with Units, but this cannot be silently corrected. CRP units unstated; no documents, independent verification or causal attribution. Exact numerical CRP claim retained here, not presented as an effect estimate.

Source context — Salvador et al. — randomized TA-65 telomere trial (2016): CMV-positive adults aged 53–87, selected exclusions, biomarker endpoint, company funding and employment/consulting ties. Not life-extension, generic equivalence, felt onset/duration or human PK evidence. PMC copy blocked; publisher body inspected.

No reliable minutes-or-hours onset. The strength and dream accounts do not timestamp a first-dose response. Telo noticed sleep and running changes within a roughly three-week generic trial; that is a different product and a follow-up window, not TA-65's onset clock. Gramson's TA-65 follow-up in Epitalon discussion (Personal report · Accessed 2026-09-30) · Telo's cycloastragenol and TA-65 comparisons (Personal report · Accessed 2026-09-30)

A strength benefit faded by about six months. That is Gramson's retrospective course, with substantial health and supplement confounding. It does not measure a single capsule's effect duration. Reliable persistence after stopping is also unknown. Gramson's TA-65 follow-up in Epitalon discussion (Personal report · Accessed 2026-09-30)

No dependable human TA-65 half-life established here. A Rapamycin.news post repeats a 4–6-hour cycloastragenol estimate from an explicitly Gemini-generated answer. It provides no checked branded-human measurement. This is AI-repeated forum lore, not a basis for dose spacing or interaction clearance. Rapa interaction with Astragalus — Gemini timing repost (Secondhand community claim · Accessed 2026-09-30)

Source context — Gramson's TA-65 follow-up in Epitalon discussion: Uncontrolled retrospective report; TA-65 dose unstated. The author's stored-enzyme depletion theory is unsupported and not adopted. Co-use and major health changes prevent attribution.

Source context — Telo's cycloastragenol and TA-65 comparisons: Historical products, anecdotal identity/quality assertions, subjective comparison and no head-to-head measurements. The generic amount is not a TA-65 dose. Later 20 mg wording does not independently restate frequency. No sourcing links or certificate authenticity claims transferred to the article.

Source context — Rapa interaction with Astragalus — Gemini timing repost: Explicitly AI-origin material, not a person's kinetic measurement. Discusses mixed Astragalus constituents and repeats speculative human claims; its human-TA-65 alignment, interaction clearance and frequency recommendations were not verified or adopted.

Every other day, with months off. Free10 described intermittent low-amount use from early 2011, sometimes pausing for months to save money. Balance instead reported daily use for several months. These are contrasting habits, not an agreed biological cycle. Astragalus, Astragaloside IV — page 70 (Community discussion · Accessed 2026-09-30)

Longer daily use and reassessment also appear. The Reddit stack account describes about six months of use. Another Reddit discussion proposes telomere testing every 6–12 months, while the preserved community record includes open-ended daily maintenance. Neither establishes how long benefits persist or a necessary break. Best supplements for protecting telomere length? (Personal report · Accessed 2026-09-30) · TA-65 — cost, alternatives and cancer debate (Community discussion · Accessed 2026-09-30)

A year-long telomere trial is separate evidence. In CMV-positive adults aged 53–87, 250 U/day showed a telomere-length signal; 1000 U/day did not show a significant improvement. The paper maps those formulations to 8 and 32 mg active and used 90 days on, 14 days off. These are study amounts and schedules, not community measurements or proof that more is better. Salvador et al. — randomized TA-65 telomere trial (2016) (Official context · Accessed 2026-09-30)

Source context — Astragalus, Astragaloside IV — page 70: Unverified products and exposure, retrospective subjective observations. Corrects the frozen ledger's attribution of balance's #2075 report to piet3r. GreenPower used related extracts; no branded-specific adverse-event rate, measured absorption, BBB penetration or causal mechanism follows.

Source context — Best supplements for protecting telomere length?: Product and units unresolved: 250 mg may be confusion with Units, but this cannot be silently corrected. CRP units unstated; no documents, independent verification or causal attribution. Exact numerical CRP claim retained here, not presented as an effect estimate.

Source context — TA-65 — cost, alternatives and cancer debate: Opinion and confounded non-TA-65 experience, not measured TA-65 effectiveness or cancer causation. Political/conspiracy assertions and unsupported equivalence calculations were not adopted. Initial bare-URL open errored; titled URL later opened successfully.

Source context — Salvador et al. — randomized TA-65 telomere trial (2016): CMV-positive adults aged 53–87, selected exclusions, biomarker endpoint, company funding and employment/consulting ties. Not life-extension, generic equivalence, felt onset/duration or human PK evidence. PMC copy blocked; publisher body inspected.

Some people want measurable aging markers. A Reddit contributor reported lower CRP after six months alongside NAC and omega-3s, without before-and-after telomere testing. CRP reflects inflammation; this stacked account does not isolate TA-65 or establish telomere lengthening. Best supplements for protecting telomere length? (Personal report · Accessed 2026-09-30)

Stacking does not establish synergy. The preserved record places TA-65 beside NMN, NR, Epitalon, spermidine, fisetin, quercetin, metformin, rapamycin, CoQ10 and PQQ. These are reported co-use names, not an established combination. The Astragalus-combination thread lacked evidence that fewer TA-65 pills plus root extract matched more pills. Double-counting related actives and changing several products at once make interpretation harder. Can You Take Astragalus & TA65 at the Same Time? (Community discussion · Accessed 2026-09-30)

One capsule per day also appears as a proposed stack. Live4Ever1972 asked whether one TA-65 pill plus Astragalus extract could replace four TA-65 pills. That was a question and proposed oral routine, not a demonstrated equivalent dose; strength and extract composition were incomplete. Can You Take Astragalus & TA65 at the Same Time? (Community discussion · Accessed 2026-09-30)

Source context — Best supplements for protecting telomere length?: Product and units unresolved: 250 mg may be confusion with Units, but this cannot be silently corrected. CRP units unstated; no documents, independent verification or causal attribution. Exact numerical CRP claim retained here, not presented as an effect estimate.

Source context — Can You Take Astragalus & TA65 at the Same Time?: Proposed routines and questions, not verified dose-response or synergy. Capsule Units, extract composition and reliable outcomes missing; commercial links excluded.

Unsettling dreams and unchanged dreams both occur. Free10 found realistic dreams disturbing enough to change timing; balance noticed no dream change. Dream intensity is not evidence of absorption or brain rejuvenation. Astragalus, Astragaloside IV — page 70 (Community discussion · Accessed 2026-09-30)

Related extracts can have their own adverse effects. GreenPower described dry mouth, drowsiness, headache and wanting more sleep with varying Astragalus-related products. These are not verified branded TA-65 adverse-event rates. Astragalus, Astragaloside IV — page 70 (Community discussion · Accessed 2026-09-30)

Cancer concerns remain unresolved by anecdotes. Community debate includes worries about extending damaged cells' survival. That does not prove TA-65 causes cancer. The year-long trial excluded people with current or previous cancer, so its reassuring observations do not answer that population's risk. TA-65 — cost, alternatives and cancer debate (Community discussion · Accessed 2026-09-30) · Salvador et al. — randomized TA-65 telomere trial (2016) (Official context · Accessed 2026-09-30)

A biomarker is not demonstrated life extension. That study had company funding and employment or consulting ties. Its telomere findings do not establish longer human life, visible youth or a lasting subjective benefit. Salvador et al. — randomized TA-65 telomere trial (2016) (Official context · Accessed 2026-09-30)

Anti-aging advertising has faced FTC action. The FTC's 2018 final order settled unsupported advertising charges and required reliable support for future claims. Endorsements and commercial presentations should be read with that history in mind. FTC final consent order in TA Sciences advertising case (2018) (Official context · Accessed 2026-09-30)

Source context — Astragalus, Astragaloside IV — page 70: Unverified products and exposure, retrospective subjective observations. Corrects the frozen ledger's attribution of balance's #2075 report to piet3r. GreenPower used related extracts; no branded-specific adverse-event rate, measured absorption, BBB penetration or causal mechanism follows.

Source context — TA-65 — cost, alternatives and cancer debate: Opinion and confounded non-TA-65 experience, not measured TA-65 effectiveness or cancer causation. Political/conspiracy assertions and unsupported equivalence calculations were not adopted. Initial bare-URL open errored; titled URL later opened successfully.

Source context — Salvador et al. — randomized TA-65 telomere trial (2016): CMV-positive adults aged 53–87, selected exclusions, biomarker endpoint, company funding and employment/consulting ties. Not life-extension, generic equivalence, felt onset/duration or human PK evidence. PMC copy blocked; publisher body inspected.

Source context — FTC final consent order in TA Sciences advertising case (2018): Historical advertising enforcement, not proof of biological inefficacy, cancer causation or current product prohibition. Initial direct open errored; shorter legacy URL redirected successfully to this exact page.